Agilis Biotherapeutics Presents at CNS Diseases World Summit and 8th Annual CNS Partnering and Deal-Making Conference

Cambridge, MA, September 12, 2015 -- Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Mark Pykett, President and CEO of Agilis, moderated the session "Partnering and Licensing in CNS" and was a panel participant in the session "Partnering with Patient Groups to Advance Research" at GTC Bio's CNS Diseases World Summit and 8th Annual CNS Partnering and Deal-Making Conference in Philadelphia, PA. In the sessions, Dr. Pykett spoke about advances in gene therapy approaches to serious CNS diseases and the growing momentum in the use of gene therapy for rare disorders, presenting Agilis' recent progress in its programs for Friedreich's Ataxia and Angelman Syndrome and emphasizing the instrumental role that patients, families and advocacy groups play in accelerating the development of therapeutic interventions for rare diseases. Dr. Pykett noted the particular efficiencies that can be realized in drug development for rare disorders and how partnering with advocacy groups can enhance clinical and regulatory progress.

GTCbio is a global leader in conferences and events which facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. The CNS Diseases World Summit is a leading forum for industry, academia, government agencies, and financing bodies to gather at the interface of research, partnerships, funding, and commercialization. The CNS Partnering and Deal-Making Conference is a concurrent partnering and business development meeting for global biotechnology and pharmaceutical companies, patient groups and foundations, government agencies, investors, and regulatory experts to discuss partnering strategies as well as emerging research areas and trends.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809